Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Favorable benefit/risk profile across the entire dose range,
with no dose-dependent pattern of AEs (2/3)
More patients achieved complete control (UAS7=0)
UAS7=0 vs. placebo (n=43)
Response rate %
(90% CI)
100-
90-
80
70
60
50
40-
30-
20
10-
0
1
2
G Placebo(N=42) ■■■■ LOU064 25mg b.i.d.(N=43)
9
10
11
12
Remibrutinib demonstrated good tolerability across
the entire dose range tested with no safety signals
Key safety data include:
✓ No dose dependent increase of, treatment interruption
or discontinuation due to LFT elevations
✓ No dose dependent cytopenias, treatment interruption
or discontinuation due to low blood cell counts
✓ No clinically relevant adverse events associated
with BTK inhibitor class (e.g. infections, cytopenias,
bleeding, hepatic events) across the dose range tested
■ More patients on remibrutinib achieved complete control, i.e. complete
absence of hives and itch (UAS7=0) over 12 week treatment period
High response rate maintained, up to end of treatment
First oral therapy to advance to Ph3 in CSU in 2021 in H1 antihistamines inadequate responders.
Best-in-class profile based on positive benefit/risk profile. Ph3 studies in CSU expected to start Q4 2021
AE - Adverse events CSU - chronic spontaneous urticaria UAS7 - weekly Urticaria Activity Score b.i.d. two times a day
17 Investor Relations | Q3 2021 Results
3
INNOVATION
1 NOVARTIS | Reimagining MedicineView entire presentation